<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02699086</url>
  </required_header>
  <id_info>
    <org_study_id>Phase II BLI-1008-001</org_study_id>
    <nct_id>NCT02699086</nct_id>
  </id_info>
  <brief_title>A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD)</brief_title>
  <official_title>A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD), Part I</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioLite, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioLite, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial was to determine the effective doses and treatment period
      of PDC-1421 Capsule in subjects with ADHD.

      The secondary objective was to evaluate the safety of PDC-1421 Capsule in subjects receiving
      PDC-1421 at various dose levels.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">August 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 10, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Attention-Deficit Hyperactivity Disorder-Rating Scale-IV (ADHD-RS-IV)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The primary endpoint is the change of ADHD Rating Scale-IV (ADHD-RS-IV) total score from baseline up to Week 8 of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conners' Adult Attention- Deficit/Hyperactivity Disorder Rating Scale-Self Report: Short Version (CAARS-S:S)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change from baseline in the Conners' Adult Attention-Deficit/Hyperactivity Disorder Rating Scale-Self Report: Short Version (CAARS-S:S) 18-Item total ADHD symptom score up to 8 weeks treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-ADHD- Severity (CGI-ADHD-S) and Clinical Global Impression-ADHD- improvement (CGI-ADHD-I)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Clinical Global Impression-ADHD- Severity (CGI-ADHD-S) and Clinical Global Impression-ADHD- improvement (CGI-ADHD-I) score of 2 or lower.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Attention-Deficit Hyperactivity Disorder (ADHD)</condition>
  <arm_group>
    <arm_group_label>1 PDC-1421 Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 PDC-1421 Capsule, trice daily, p.o. after meal for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 PDC-1421 Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 PDC-1421 Capsules, trice daily, p.o. after meal for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDC-1421 Capsule</intervention_name>
    <description>PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.</description>
    <arm_group_label>1 PDC-1421 Capsule</arm_group_label>
    <arm_group_label>2 PDC-1421 Capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18-70 years

          2. Female subjects of child-bearing potential must test negative to pregnancy and use
             appropriate birth control method from the beginning of study to the 15 days later
             after ending of study

          3. Subjects must be able to understand and willing to sign informed consent

          4. Able to discontinue the use of any psychotropic medications for the treatment of ADHD
             symptoms at screening

          5. Meet strict operational criteria for adult ADHD according to the Diagnostic and
             Statistical Manual of Mental Disorders, 5th Edition (DSM-5)

          6. A total score of 20 or higher on the 18-item total ADHD symptoms score of Conners'
             Adult Attention-Deficit/Hyperactivity Disorder Rating Scale-Self Report: Short Version
             (CAARS-S:S) at screening

          7. Have a moderate or severe symptom of ADHD with score of 4 or higher in Clinical Global
             Impression-ADHD-Severity (CGI-ADHD-S) at screening

        Exclusion Criteria:

          1. Have any clinically significant concurrent medical condition (endocrine, renal,
             respiratory, cardiovascular, hematological, immunological, cerebrovascular,
             neurological, anorexia, obesity or malignancy) that has become unstable and may
             interfere with the interpretation of safety and efficacy evaluations

          2. Have any clinically significant abnormal laboratory, vital sign, physical examination,
             or electrocardiogram (ECG) findings at screening that, in the opinion of the
             investigator, may interfere with the interpretation of safety or efficacy evaluations

          3. Have known serological evidence of human immunodeficiency virus (HIV) antibody

          4. Are pregnant as confirmed by a positive pregnancy test at screening

          5. Have QTc values &gt;450 msec at screening using Fridericia's QTc formula

          6. Have current of bipolar and psychotic disorders

          7. Have a current major depression disorder, obsessive-compulsive disorder,
             post-traumatic stress disorder, generalized anxiety disorder, panic disorder and
             eating disorder (also if treated but not currently symptomatic)

          8. Have any history of a significant suicide attempt, or possess a current risk of
             attempting suicide, in the investigator's opinion, based on clinical interview and
             responses provided on the Beck Scale for Suicidal Ideation (BSS)

          9. Have a history of jailing or imprisonment in the past 6 months due to worsening of
             symptoms of ADHD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith R McBurnett, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of California San Francisco, School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frank C Liu, MD</last_name>
    <phone>886-3-668-5386</phone>
    <email>liu3763@bioliteinc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSF Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keith R McBurnett, PhD</last_name>
      <phone>415-476-7892</phone>
      <email>Keith.McBurnett@ucsf.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 1, 2016</study_first_submitted>
  <study_first_submitted_qc>March 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2016</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

